JP2006176498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006176498A5 JP2006176498A5 JP2005335154A JP2005335154A JP2006176498A5 JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5 JP 2005335154 A JP2005335154 A JP 2005335154A JP 2005335154 A JP2005335154 A JP 2005335154A JP 2006176498 A5 JP2006176498 A5 JP 2006176498A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hmg
- coa reductase
- reductase inhibitor
- ubidecarenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 9
- 229960004747 ubidecarenone Drugs 0.000 claims 9
- 208000013824 Acidemia Diseases 0.000 claims 7
- 208000010444 Acidosis Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- 229960001495 pravastatin sodium Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005335154A JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004341493 | 2004-11-26 | ||
| JP2004341493 | 2004-11-26 | ||
| JP2005335154A JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006176498A JP2006176498A (ja) | 2006-07-06 |
| JP2006176498A5 true JP2006176498A5 (enrdf_load_stackoverflow) | 2009-01-29 |
| JP4896501B2 JP4896501B2 (ja) | 2012-03-14 |
Family
ID=36730936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005335154A Expired - Fee Related JP4896501B2 (ja) | 2004-11-26 | 2005-11-21 | 血中遊離脂肪酸低下作用を有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4896501B2 (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
| TWI636783B (zh) * | 2012-04-18 | 2018-10-01 | 友霖生技醫藥股份有限公司 | 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69001146T2 (de) * | 1989-01-18 | 1993-10-07 | Merck & Co Inc | Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren. |
| US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| AUPR177300A0 (en) * | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
| JP2003081873A (ja) * | 2001-06-28 | 2003-03-19 | Takeda Chem Ind Ltd | 臓器機能障害および臓器不全の予防治療剤 |
| MXPA04010392A (es) * | 2002-04-23 | 2005-08-18 | Nutrition 21 Inc | Composiciones de cromo y metodos para utilizar las mismas para inhibir resistencia a insulina inducida por droga. |
-
2005
- 2005-11-21 JP JP2005335154A patent/JP4896501B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2010047616A5 (enrdf_load_stackoverflow) | ||
| WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
| Awad et al. | Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis | |
| JP2007523049A5 (enrdf_load_stackoverflow) | ||
| JP2008509132A5 (enrdf_load_stackoverflow) | ||
| JP2004537553A5 (enrdf_load_stackoverflow) | ||
| EA200970359A1 (ru) | Статин и омега-3 жирные кислоты для снижения уровней аро-в | |
| JP2007238598A5 (enrdf_load_stackoverflow) | ||
| JP2007277267A5 (enrdf_load_stackoverflow) | ||
| JP2008050367A5 (enrdf_load_stackoverflow) | ||
| NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| AR081032A1 (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| WO2018064654A1 (en) | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof | |
| JP2005511619A5 (enrdf_load_stackoverflow) | ||
| WO2009059717A3 (en) | Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use | |
| JP2008515980A5 (enrdf_load_stackoverflow) | ||
| JP2010505866A5 (enrdf_load_stackoverflow) | ||
| JP2008063322A5 (enrdf_load_stackoverflow) | ||
| JP2006176498A5 (enrdf_load_stackoverflow) | ||
| JP2014521738A5 (enrdf_load_stackoverflow) | ||
| JP2013536408A5 (enrdf_load_stackoverflow) | ||
| EP2780002A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| JP2008513379A5 (enrdf_load_stackoverflow) | ||
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии |